HSD17B6 and hepatocellular carcinoma: First, we analyzed four microarray datasets from the Oncomine Platform, and found that HSD17B6 transcript levels were significantly reduced in patients with HCC in all four datasets (p < 0.0001, Fig. 2a–d).